ATE429228T1 - Derivate von piperazine-2-carboxamide - Google Patents

Derivate von piperazine-2-carboxamide

Info

Publication number
ATE429228T1
ATE429228T1 AT04708776T AT04708776T ATE429228T1 AT E429228 T1 ATE429228 T1 AT E429228T1 AT 04708776 T AT04708776 T AT 04708776T AT 04708776 T AT04708776 T AT 04708776T AT E429228 T1 ATE429228 T1 AT E429228T1
Authority
AT
Austria
Prior art keywords
piperazine
carboxamide
derivatives
labor
dysmenorrhea
Prior art date
Application number
AT04708776T
Other languages
English (en)
Inventor
Patrick Page
Catherine Jorand-Lebrun
Matthias Schwarz
Russell J Thomas
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Application granted granted Critical
Publication of ATE429228T1 publication Critical patent/ATE429228T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04708776T 2003-02-14 2004-02-06 Derivate von piperazine-2-carboxamide ATE429228T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03003422 2003-02-14
PCT/EP2004/050093 WO2004071390A2 (en) 2003-02-14 2004-02-06 Piperazine-2-carboxamide derivatives

Publications (1)

Publication Number Publication Date
ATE429228T1 true ATE429228T1 (de) 2009-05-15

Family

ID=32864935

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04708776T ATE429228T1 (de) 2003-02-14 2004-02-06 Derivate von piperazine-2-carboxamide

Country Status (10)

Country Link
US (1) US8404690B2 (de)
EP (1) EP1592389B1 (de)
JP (1) JP4825664B2 (de)
AT (1) ATE429228T1 (de)
AU (1) AU2004212335A1 (de)
CA (1) CA2513716A1 (de)
DE (1) DE602004020734D1 (de)
ES (1) ES2324535T3 (de)
NO (1) NO20053991L (de)
WO (1) WO2004071390A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1511488B1 (de) 2002-06-12 2013-05-22 Symphony Evolution, Inc. Humane adam-10-hemmer
ES2399047T3 (es) * 2002-09-20 2013-03-25 Merck Serono Sa Derivados de piperazina y procedimiento de uso
PT1558582E (pt) 2003-07-22 2006-05-31 Arena Pharm Inc Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
EP1778669A2 (de) 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase-inhibitoren
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8017612B2 (en) * 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
US7943622B2 (en) 2006-06-06 2011-05-17 Cornerstone Therapeutics, Inc. Piperazines, pharmaceutical compositions and methods of use thereof
WO2007146066A2 (en) * 2006-06-06 2007-12-21 Critical Therapeutics, Inc. Novel piperazines, pharmaceutical compositions and methods of use thereof
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
EP2508177A1 (de) 2007-12-12 2012-10-10 Glaxo Group Limited Kombinationen mit 3-phenylsulfonyl-8-piperazinyl-1yl-chinolin
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
EP3215150B1 (de) * 2014-11-07 2022-07-20 The Regents of The University of Michigan Inhibitoren des myocardin-verwandten transkriptionsfaktors und serumreaktionsfaktor (mrtf srf/)-vermittelte gentranskription und verfahren zur verwendung davon
WO2016201373A1 (en) 2015-06-12 2016-12-15 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
WO2019104011A1 (en) * 2017-11-21 2019-05-31 Biomarin Pharmaceutical Inc. Ceramide galactosyltransferase inhibitors for the treatment of disease
WO2020028221A1 (en) * 2018-07-30 2020-02-06 Biomarin Pharmaceutical Inc. Ceramide galactosyltransferase inhibitors for the treatment of disease
EP4021210B1 (de) * 2019-08-26 2026-04-01 Société des Produits Nestlé S.A. Myo-inositol und vorbeugung einer frühgeburt
WO2021037698A1 (en) * 2019-08-26 2021-03-04 Société des Produits Nestlé S.A. Myo-inositol and the prevention of pprom
WO2023215205A1 (en) * 2022-05-06 2023-11-09 Merck Sharp & Dohme Llc Orexin receptor agonists
WO2024107615A1 (en) * 2022-11-17 2024-05-23 Merck Sharp & Dohme Llc Orexin receptor agonists
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6450818A (en) 1987-08-20 1989-02-27 Tsumura & Co Prostaglandin f2alpha-inhibitor
US6271201B1 (en) 1993-07-15 2001-08-07 Board Of Regents, The University Of Texas System Methods for the selective regulation of placental prostanoids and inhibition of labor using IGF-I
TW472047B (en) 1994-02-04 2002-01-11 Merck & Co Inc Process for making HIV protease inhibitors
US5612484A (en) * 1995-05-18 1997-03-18 Merck & Co., Inc. Process for making HIV protease inhibitors
CA2238306A1 (en) * 1995-12-08 1997-06-12 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
CN1181069C (zh) * 1998-12-23 2004-12-22 先灵公司 新的法尼基蛋白转移酶抑制剂
DE60034571T2 (de) * 1999-06-15 2007-12-27 Aventis Pharmaceuticals Inc. Festphasensynthese von n,n-disubstituierten diazacycloalkylcarboxy-derivaten
EP1322610A2 (de) * 2000-09-29 2003-07-02 Millennium Pharmaceuticals, Inc. Faktor xa inhibitoren abgeleitet von piperazin
EP1429648A4 (de) 2001-01-24 2005-03-30 Univ Arizona Verfahren zum screening von substanzen, die die wechselwirkung des fp?prostanoidrezeptors mit einer verbindung mit pgf 2 ??wirksamkeit hemmt, und verfahren zur behandlung von krebs
ES2399047T3 (es) 2002-09-20 2013-03-25 Merck Serono Sa Derivados de piperazina y procedimiento de uso

Also Published As

Publication number Publication date
AU2004212335A8 (en) 2004-08-26
US8404690B2 (en) 2013-03-26
EP1592389B1 (de) 2009-04-22
DE602004020734D1 (de) 2009-06-04
WO2004071390A2 (en) 2004-08-26
WO2004071390A3 (en) 2004-12-23
NO20053991L (no) 2005-08-26
ES2324535T3 (es) 2009-08-10
JP2006517566A (ja) 2006-07-27
AU2004212335A1 (en) 2004-08-26
EP1592389A2 (de) 2005-11-09
US20070142391A1 (en) 2007-06-21
CA2513716A1 (en) 2004-08-26
JP4825664B2 (ja) 2011-11-30

Similar Documents

Publication Publication Date Title
ATE429228T1 (de) Derivate von piperazine-2-carboxamide
EA201391705A1 (ru) Триазолпиридиновые ингибиторы 11-бета-гидроксистероиддегидрогеназы типа i
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
EA200401270A1 (ru) Тиазолидинкарбоксамидные производные как модуляторы рецептора простагландина f
NO20080963L (no) Piperidinyl-substiuerte isokinolinderivater som Rho-kinaseinhibitorer
DE60204322D1 (de) Stickstoffmonoxid bildende zusammensetzungen zur behandlung von nagelbettinfektionen
MY135841A (en) Novel benzodioxoles
NO20073783L (no) Pyrrolidininhibitorer for IAP
DE60315146D1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
MY140031A (en) Carbonyl compounds
TW200714589A (en) Phenylacetamides suitable as protein kinase inhibitors
NO20082096L (no) Azaindol-2-karboksamidderivativer
TW200630374A (en) Thiazolyldihydroindazoles
ATE347555T1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
ATE478054T1 (de) Benzimidazolderivate
ATE429916T1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
UA85676C2 (en) Carbonyl compounds
ECSP055537A (es) Monoclorhidrato de 2,5-diona-3-(1-metil-1h-indol-3-il)-4-[1-(piridin-2-ilmetil)piperidin-4-il]-1h-indol-3-il]-1h-pirrol cristalino
ATE399175T1 (de) Hemmstoffe der urokinase, ihre herstellung und verwendung
NO20080144L (no) Spiro-benzimidazoler som inhibitorer av magesyre og sekresjon
BRPI0519267A2 (pt) derivado de quinolina, seu uso, produÇço e medicamento contendo o mesmo
DK1644385T3 (da) Siliciumforbindelser og deres anvendelse
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
DE60219940D1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
EA200701852A1 (ru) Производные аминокислот

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties